hogfan''s picks

[hogfan2]

http://stockzoa.com/fund/soros-fund-management-llc/

[ToldYaSo]

hogfan....just found your board....Arkie ex-pat here from the springs city! whoooopiggg!

Like your picks....nice board!!

[hogfan2]

GBIM undiscovered and Cheapest Hepatitis Play you can get on the Stockmarket . Important Phase 2 Results of their Hep B Drug (partnered with Gilead) in 2Q if Positive then you can expect a share price explsoion because of its extreme low float .

Globeimmune (GBIM)

Market Cap: $42 Million
Cash $17 Million

Price $7.30
Shares Out: 5.7 Million


GBIM is the Cheapest Hepatitis Play you can get on the Stockmarket with a laughable Market Cap of $42 Million and $17 Million in Cash . GBIM is partnered with World Class Biotechs Gilead and Celgene and Celgene is the largest Shareholder of this undiscovered Goldmine . There are only 5.7 Million Shares Outstanding means if Phase 2 results are positive then this one will explode like a Nuclear bomb .GL





GS-US-330-0101, or the 0101 trial, is a randomized Phase 2 clinical trial, initiated in 2013, investigating GS-4774 in combination with ongoing oral antiviral treatment in patients with chronic HBV infection. The 0101 trial is a multicenter, multinational trial that enrolled 175 patients in a randomized, open-label design comparing three different doses of GS-4774, administered in combination with oral antiviral therapy versus antiviral treatment alone. The primary endpoint for this trial is decline in serum HBV surface antigen, or HBsAg. The 0101 trial is fully-enrolled, and 48-week results are expected to be available in the first half of 2015. These results may be submitted to an upcoming scientific conference.

We have two strategic collaborations with leading biotechnology companies. In October 2011, Gilead Sciences, Inc., or Gilead, exclusively licensed product candidates intended to treat chronic hepatitis B virus, or HBV, infection. Celgene Corporation, or Celgene, entered into a collaboration and option agreement for certain oncology product candidates in May 2009. Under this agreement, in July 2013 Celgene exercised its option for a worldwide, exclusive license to the GI-6300 program, which is a Tarmogen program targeting the brachyury protein. Brachyury plays a role in the metastatic progression of certain cancers and is believed to be fundamental in the formation of chordomas, rare bone tumors of the spine. Through March 31, 2014, we have received over $60 million from these collaborations.

[hogfan2]

ELTP...higher lows...nice looking chart...hog

[sharpei]

For lots of reasons, yes, Conix.

[conix]

ELTP has put in a base, imo

[sharpei]

ELTP:

Two Clinical Trials announced:

https://clinicaltrials.gov/ct2/show/NCT02401750?term=%22Elite+Laboratories%2C+Inc%22&rank=2;




https://www.clinicaltrials.gov/ct2/show/NCT02401750?term=Elite+Laboratories%2C+Inc&rank=2

[sharpei]

ELTP ready for its annual trip to the moon; one year ago @ .97 and more products launched; company at the cusp of FDA 'greenlight' submission of ELI-200 first of 17 generic abuse deterrent opioids; plant expansion and staff expansion; ten qtrs. of positive cash flow; debt reduction completed; will fly past .97.

Daily two months chart:


(Not intended as inducement to buy or sell.)

[hogfan2]

https://yixiblog.wordpress.com/about/

[Citrati]

hog, ya gonna have a nice winner if you fill that gap.
Be Green Always

[hogfan2]

$NSPR up over 5% on increasing volume...link back for nice looking chart...hog

[hogfan2]

GNCA chart

[hogfan2]

NSPR chart

[hogfan2]

$STWS...nice looking chart conix....good volume today...hog

[conix]

STWS is starting to break out, sharpei.

[Solarman]

IMNP will check it out. Please look at MMMW with its new solar cost cutting new product . MMMW also has less than $1 million market cap.

[hogfan2]

http://scr.zacks.com/files/February-24-2015_CPXX_Zeng_v001_l07hbg.pdf

[hogfan2]

IMNP...roth 3/11

[hogfan2]

CPXX...http://investorshub.advfn.com/boards/read_msg.aspx?message_id=111134319&txt2find=cpxx

Roth 3/9
financing recently

[hogfan2]

ELTP...i like it thx...hog

[sharpei]

ELTP headed back to .97 and beyond; ten qtrs. of positive cash flow; seasoned CEO (moved from sr. position at Activis June 2013); seven of twelve prescriptions commercialized; doubled manfg space and eqpt; paid off debt; phase III trial to begin c. March 15 on first of eight two bead opioid (in addition to the afore-mentioned drugs)Abuse Resistant Therapy (ELI-200), expected H1 2016 launch; highly qualified team of researchers, attys and accountant in addition to superior mgmt. team.

Closed today @ $.264.

(Three mos daily-March 02, 2015);

(One year daily; March 05, 2014 $.97)

[hogfan2]

http://www.j3sg.com/Reports/Stock-Insider/Generate-Institution-Portfolio.php?institutionid=4674&DV=yes&viewArchive=no&archiveDateIn=

[Seel]

Hi hogfan2,
I'm long IDRA, SYN, CUR. CYNAF - I've been in and out but recently back in and will keep adding small bits under 1.10. Won't be long with them. Will go very long with APHB once new management cleans up financials and proves their talent. Really excited about them actually. LGviolet turned me on to APHB. Considering going long in Sangamo. tpizzazz24 turned me on to CRMD and sent me Sangamo reminder - its been on my watch list for a while. Now deciding whether CRMD or MRIC will be main device in portfolio. And other than that - I'll do a few ph2 run-up plays to feed the long positions over the course of the year.
Take care!
Seel

[hogfan2]

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=109436277&txt2find=fcsc

[hogfan2]

BIAD...http://www.publicwire.com/bio-amd-inc-agreement-with-sysmex-general-update/

[hogfan2]

http://seekingalpha.com/article/2817476-rexahns-lead-drug-rxminus-3117-beats-lillys-gemzar-in-one-to-one-face-off?auth_param=117cp:1abamag:96ba480782bdfe74219a55e3a966f278

http://ih.advfn.com/p.php?pid=nmona&article=65000024&symbol=RNN

http://www.thelifesciencesreport.com/pub/co/5343

http://www.rexahn.com/cms/portfolio/

[hogfan2]

$TGTX chart...

[hogfan2]

$CYNAF cart...

[hogfan2]

$NVIV...http://bionapcfa.blogspot.com/2015/01/invivo-patient-no1-shows-unexpected.html

[hogfan2]

https://twitter.com/search?q=bnhlf&src=typd

[hogfan2]

http://biotechnologyfocus.ca/flipping-switch-parkinsons-patients/

[hogfan2]

$BNHLF...added today 0.2147...http://seekingalpha.com/instablog/13833412-sujan-lahiri/3273535-bioniche-a-home-run-buying-opportunity-in-biotech

[hogfan2]

$RNN...intend to add tomorrow...hog
$RNN...new article out at seekingalpha...disclosure author is long $RNN..

Rexahn's Lead Drug RX-3117 Beats Lilly's Gemzar In One-To-One Face Off

http://seekingalpha.com/article/2817476-rexahns-lead-drug-rxminus-3117-beats-lillys-gemzar-in-one-to-one-face-off#comments_header

[hogfan2]

$NVIV nice video of first pt's ongoing recovery...hog

[hogfan2]

$AMBS...closed @.0985...up 10% for the day...hog

[hogfan2]

$ANTB up 13% to 1.70...hog

[hogfan2]

$ADMP...buying on dip closer to 5 bucks....hog
http://microcapresearch.com/wp-content/uploads/2015/01/Latest-Report.pdf

[hogfan2]

$ANTB...moving up...1.65...hog

[hogfan2]

$AMBS...starter position @ .09...hog

[hogfan2]

$ANTB...AntriaBio Announces Completion Of PK/PD Studies Of AB101 In Two Species
http://www.biospace.com/News/antriabio-announces-completion-of-pk-pd-studies-of/360192

[hogfan2]

http://scr.zacks.com/files/Nov-12-2014_ANTB_Napodano_v001_i4bjye.pdf

[hogfan2]

$CUR...added..more..hog

[hogfan2]

$NVIV...i see pps increasing with anticipation of next pt and company confirmed results of 1st pt...this should occur withing the next 2 weeks or so...hog

[hogfan2]

RNN...http://ih.advfn.com/p.php?pid=nmona&article=65000024&symbol=RNN

[hogfan2]

$ACRX...http://seekingalpha.com/article/2789515-a-little-impatience-and-a-lot-of-skepticism-provides-an-excellent-risk-reward-in-acelrx-pharmaceuticals

[hogfan2]

ACRX chart...on watch..hog

[hogfan2]

ATHX chart...monster...hog

[hogfan2]

NVIV and IPCI....my 2 largest holdings...expecting good things this month...hog

[hogfan2]

biotech article...from jason napodano...hog
http://seekingalpha.com/article/2797975-15-biotech-names-for-2015?page=2

[hogfan2]

$ZGNX...Zogenix 2015 Expectations and Developments Drive Price Upward: Analyst Report Issued by BrokerBank Securities, Inc.

NEW YORK, Jan. 5, 2015 /PRNewswire/ -- Zogenix Inc. (NASDAQ: ZGNX) is a California-based pharmaceutical company that develops and commercializes therapies for the treatment of central nervous system disorders and pain. The company's two main products include Zohydro (a single-entity extended-release hydrocodone for the treatment of moderate to severe chronic pain) and Relday (an injectable formulation of risperidone formulated to treat the symptoms of schizophrenia and bipolar disorder, and which is in a Phase I clinical trial). Zogenix was founded in 2006 with its headquarter located in San Diego, California.

Since its IPO in 2010, Zogenix stock reached its peak twice, one of them was on Feb 10th 2014 at $4.7. The stock had been experiencing poor performance throughout 2014 despite the fact that its Q3 result outperformed the street's expectation. However, the stock has shown positive signs recently, and it seems to be a good time to enter the market due to its current underprice and several catalysts for growth in 2015.

The November 2014 issue of the Journal of Pain Research published a long-term, open-label study that explained the safety, effectiveness, and tolerability of Zohydro ER.

Further, Zogenix has participated in multiple healthcare conferences that took place in New York City, including the Stifel 2014 Healthcare Conference in November 2014, and the Oppenheimer 25th Annual Healthcare Conference in December 2014.

For the full research report with analyst comments, recommendation and price target on Zogenix Inc. please follow the link. There is no cost obligation required to view analyst report:

http://bit.ly/-ZGNX-AnalystReport

Copy and paste to browser may be required.

http://money.cnn.com/news/newsfeeds/articles/prnewswire/DE99988.htm

ZGNX has not compensated Small Cap IR, BrokerBank Securities, Inc., or Nhung Nguyen, Analyst for the creation or
dissemination of this report. Small Cap IR and BrokerBank Securities, Inc., are not responsible for any error which may be
occasioned at the time of printing of this document or any error, mistake or shortcoming. Small Cap IR and BrokerBank Securities,
Inc. do not hold any positions in ZGNX. No liability is accepted by Small Cap IR and BrokerBank Securities, Inc. whatsoever for
any direct, indirect or consequential loss arising from the use of this document. Small Cap IR and BrokerBank Securities, Inc.
expressly disclaims any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance
placed on the information in this document. Small Cap IR and BrokerBank Securities, Inc. do not (1) guarantee the accuracy,
timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.
Small Cap IR is the party responsible for hosting the full analyst report. BrokerBank Securities in the party responsible for issuing
the press release and Nhung Nguyen, Analyst, is the author of research report. Small Cap IR has compensated Nhung Nguyen,
Analyst two fifty dollars for the right to disseminate this report. BrokerBank Securities has been compensated one hundred dollars
to issue press release by Small Cap IR. Information in this report is fact checked and produced on a best efforts basis by Nhung
Nguyen, Analyst.